拉米夫定联合苦参素胶囊治疗慢性乙型肝炎临床观察

目的观察拉米夫定联合苦参素胶囊治疗慢性乙型肝炎的临床疗效。方法将97例慢性乙型肝炎患者随机分为治疗组（49例）和对照组（48例）;治疗组给予口服拉米夫定和苦参素胶囊治疗,对照组仅口服拉米夫定,疗程6个月。结果治疗组总有效率为81.63%,对照组为68.75%（P〈0.05）。治疗后两组丙氨酸氨基转移酶（ALT）、总胆红素（TBIL）均降低（P〈0.05）,且治疗组的降低较对照组明显（P〈0.05）。治疗组HBeAg和HBV-DNA阴转率分别为53.06%和65.31%,均高于对照组的41.67%和31.25%（P〈0.05）。结论拉米夫定联合苦参素胶囊治疗慢性乙型肝炎疗效确切。

Clinical observation of lamivudine and "Kushensu Capsule" in treating chronic hepatitis B

Objective To observe the clinical efficacy of lamivudine and ＂Kushensu Capsule＂ in the treatment of chronic hepatitis B.Methods Ninety-seven subjects were randomized into two groups： treatment group in which 49 cases were treated with lamivudine and ＂Kushensu Capsule＂,and control group in which 48 cases were treated with lamivudine alone,with a course of six months.Results The total effective rate was 81.63% in the treatment group and 68.75% in the control group（P0.05）.After treatment,the contents of ALT and TBIL were reduced in both groups（P0.05）,with more significant reduction in the treatment group than in the control group（P0.05）.The negative conversion rates of HBeAg and HBV-DNA were 53.06% and 65.31% in the treatment group,respectively higher than 41.67% and 31.25% in the control group（P0.05）.Conclusion Combined lamivudine and ＂Kushensu Capsule＂ is quite effective for chronic hepatitis B.